| Code | CSB-RA839793MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CHS-1000, specifically targeting LILRB2 (Leukocyte Immunoglobulin-Like Receptor B2), also known as ILT4 or CD85d. LILRB2 is an inhibitory receptor predominantly expressed on myeloid cells, including monocytes, macrophages, and dendritic cells, where it functions as a critical immune checkpoint by delivering immunosuppressive signals upon engagement with its ligands, such as classical and non-classical MHC class I molecules. This receptor plays a pivotal role in maintaining immune tolerance and regulating inflammatory responses, and its dysregulation has been implicated in various pathological conditions including cancer immune evasion, autoimmune disorders, and transplant rejection.
The reference antibody CHS-1000 has been utilized in immunological research to investigate LILRB2-mediated immune suppression and its therapeutic potential in modulating myeloid cell function. This biosimilar antibody serves as a valuable tool for researchers studying tumor microenvironment dynamics, myeloid-derived suppressor cell biology, and immune checkpoint mechanisms. It enables investigation of LILRB2's role in cancer immunotherapy resistance and the development of novel immunomodulatory strategies.
There are currently no reviews for this product.